Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

NCT02633189 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Bevacizumab

Sponsor

National Cancer Institute, Naples